Targeted Busulfan and Cyclophosphamide as Compared to Busulfan and TBI as Preparative Regimens for Transplantation in Patients with Advanced MDS or Transformation to AML

References

• Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., et al. and The French-American-British (FAB) Co-Operative Group (1982) "Proposals for the classification of the myelodysplastic syndromes", British Journal of Haematology, 51, 189 — 199.
   PubMed Web of Science ®Google Scholar
• Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., et al. (1985) "Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group", Annals of Internal Medicine, 103, 620–625.
   PubMed Web of Science ®Google Scholar
• World Health Organization Classification of Tumours. (2001) Pathology & Genetics: Tumours of Hematopoietic and Lymphoid Tissues, edited by E.S. Jaffe, N.L. Harris, H. Stein, and J.W. Vardiman, Washington, DC: IARC Press.
   Google Scholar
• Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., et al. (1997) "International scoring system for evaluating prognosis in myelodysplastic syndromes" (published erratum appears in Blood 1998; 91, 1100). Blood, 89, 2079–2088.
   PubMed Web of Science ®Google Scholar
• de Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijcicmans, P., Hayat, M., et al. (1995) "Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG)", Leukemia, 9, 1805— 1811.
   Google Scholar
• Deeg, H.J. and Appelbaum, F.R. (2000) "Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome (Re-view)", Leukemia Research, 24, 653–663.
   Google Scholar
• Deeg, Hi., Storer, B., Slattery, J.T., Anasetti, C., Doney, K.C., Hansen, JA., et al. (2002) "Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome", Blood, 100, 1201–1207.
   Google Scholar
• Anderson, J.E., Appelbaum, FR., Fisher, L.D., Schoch, G., Shulman, H., Anasetti, C., et al. (1993) "Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome", Blood, 82, 677–681.
   PubMed Web of Science ®Google Scholar
• Anderson, J.E., Appelbaum, FR., Schoch, G., Gooley, T., Anasetti, C., Bensinger, W.I., et al. (1996) "Allogeneic marrow transplanta-tion for myelodysplastic syndrome with advanced disease morphol-ogy: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors", Journal of Clinical Oncology, 14, 220–226.
   Google Scholar
• Jurado, M., Deeg, H.J., Storer, B., Anasetti, C., Anderson, J.E., Bryant, E., et al. (2002) "Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality", Biology of Blood and Marrow Transplantation, 8, 161 — 169.
   Google Scholar
• Slattery, J.T., Clift, R.A., Buckner, C.D., Radich, J., Storer, B., Bensinger, W.I., et al. (1997) "Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation", Blood, 89, 3055–3060.
   Google Scholar
• Slattery, J.T., Sanders, J.E., Buckner, C.D., Schaffer, R.L., Lambert, K.W., Langer, F.P., et al. (1995) "Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacolcinetics", Bone Marrow Transplantation, 16, 31 — 42.
   PubMed Web of Science ®Google Scholar
• Slattery, J.T. and Risler, L.J. (1998) "Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation", Therapeutic Drug Monitoring, 20, 543–549.
   PubMed Web of Science ®Google Scholar
• Deeg, Hi., Shulman, H.M., Anderson, J.E., Bryant, EM., Gooley, TA., Slattery, J.T., et al. (2000) "Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age", Blood, 95, 1188 — 1194.
   Google Scholar
• Storb, R., Deeg, Hi., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., et al. (1986) "Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia", New England Journal of Medicine, 314, 729–735.
   Google Scholar
• Nash, R.A., Furlong, T., Storb, R., Anasetti, C., Appelbaum, FR., Deeg, Hi., et al. (1997) "Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): safety analysis", Blood, 90\(Suppl. 1), 105a, #459.
   Google Scholar
• Benito, AT., Furlong, T., Martin, P.J., Anasetti, C., Appelbaum, F.R., Doney, K., et al. (2001) "Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease", Transplantation, 72, 1924 — 1929.
   Web of Science ®Google Scholar
• Carpenter, PA., Appelbaum, F.R., Corey, L., Deeg, Hi., Doney, K., Gooley, T., et al. (2002) "A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease", Blood, 99, 2712–2719.
   PubMed Web of Science ®Google Scholar
• Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.-G., Beatty, P., Hows, J., et al. (1995) "1994 Consensus conference on acute GVHD grading", Bone Marrow Transplantation, 15, 825–828.
   PubMed Web of Science ®Google Scholar
• Petersdorf, E.W., Longton, G.M., Anasetti, C., Mickelson, EM., McKinney, S.K., Smith, A.G., et al. (1997) "Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors", Blood, 89, 1818— 1823.
   Google Scholar
• Shulman, H.M., Wells, D., Gooley, T., Myerson, D., Bryant, E. and Loken, M.R. (1999) "The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry", American Journal of Clinical Pathology, 112, 513–523.
   Google Scholar
• Sievers, EL., Lange, B.J., Buckley, JD., Smith, F.O., Wells, D.A., Daigneault-Creech, C.A., et al. (1996) "Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry", Journal of the National Cancer Institute, 88, 1483–1488.
   PubMed Web of Science ®Google Scholar
• Scharf, S.J., Smith, A.G., Hansen, JA., McFarland, C. and Erlich, H.A. (1995) "Quantitative determination of bone marrow trans-plant engraftment using fluorescent polymerase chain reaction primers for human identity markers", Blood, 85, 1954–1963.
   Google Scholar
• Slavin, MA., Osborne, B., Adams, R., Levenstein, Mi., Schoch, HG., Feldman, A.R., et al. (1995) "Efficacy and safety of fluconazole for fungal infections after marrow transplant - a prospective, randomized, double-blind study", Journal of Infectious Diseases, 171, 1545–1552.
   Google Scholar
• Boeckh, M., Stevens-Ayers, T. and Bowden, R.A. (1996) "Cyto-megalovirus pp antigenemia after autologous marrow and peripheral blood stem cell transplantation", Journal of Infectious Diseases, 174, 907 — 912.
   Web of Science ®Google Scholar
• Kaplan, E.L. and Meier, P. (1958) "Nonparametric estimation from incomplete observations", Journal of the American Statistical Association, 53, 457 — 481.
   Web of Science ®Google Scholar
• Kalbfleisch, J.D. and Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons.
   Google Scholar
• Gooley, TA., Leisenring, W., Crowley, J. and Storer, B.E. (1999) "Estimation of failure probabilities in the presence of competing risks: new representations of old estimators", Statistics in Medicine, 18, 695–706.
   Google Scholar
• Clift, R.A., Buckner, CD., Appelbaum, F.R., Bearman, S.I., Petersen, F.B., Fisher, L.D., et al. (1990) "Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens", Blood, 76, 1867— 1871.
   Web of Science ®Google Scholar
• Clift, R.A., Buckner, C.D., Appelbaum, F.R., Sullivan, KM., Storb, R. and Thomas, E.D. (1998) "Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia (Letter)", Blood, 92, 1455 — 1456.
   Google Scholar
• Deeg, Hi., Spitzer, T.R., Cottler-Fox, M., Cahill, R. and Pickle, L.W. (1991) "Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophy-laxis", Bone Marrow Transplantation, 7, 193— 198.
   Web of Science ®Google Scholar
• Runde, V., de Witte, T., Arnold, R., Gratwohl, A., Hermans, J., van Biezen, A., et al. (1998) "Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodys-plastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation", Bone Marrow Transplan-tation, 21, 255–261.
   Google Scholar
• Sierra, J., Perez, W.S., Rozman, C., Carreras, E., Klein, J.P., Rizzo, JD., et al. (2002) "Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia", Blood, 100, 1997— 2004.
   Web of Science ®Google Scholar
• Cutler, C., Lee, S., Greenberg, P., Deeg, J., Antin, J., Perez, W., et al. (2002) "A decision analysis of allogeneic stem cell transplanta-tion for MDS: delayed transplantation for low risk MDS is associated with improved outcome", Blood, 100 (Part 1), 74a, #270.
   Google Scholar
• Wells, D.A., Benesch, M., Loken, MR., Vallejo, C., Myerson, D., Leisenring, W.M., et al. (2003) "Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation", Blood, 102, 394–403.
   Google Scholar
• Anderson, J.E., Gooley, TA., Schoch, G., Anasetti, C., Bensinger, W.I., Clift, R.A., et al. (1997) "Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy", Blood, 89, 2578 — 2585.
   Google Scholar
• Scott, B.L., Deeg, H.J. and Appelbaum, F.R. (2003) "Pre-transplant induction chemotherapy and post-transplant relapse in patients with advanced MDS", Blood, 102 (Part 1), 152A, #523.
   Google Scholar
• Pagel, J.M., Matthews, D.C., Appelbaum, F.R., Bernstein, I.D. and Press, 0.W. (2002) "The use of radioimmunoconjugates in stem cell transplantation (Mini-review)", Bone Marrow Transplantation, 29, 807 — 816.
   Web of Science ®Google Scholar
• Bornhäuser, M., Storer, B., Slattery, J.T., Appelbaum, F.R., Deeg, Hi., Hansen, J., et al. (2003) "Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells", Blood, 102, 820–826.
   Google Scholar
• McDonald, GB., Slattery, J.T., Bouvier, ME., Ren, S., Batchelder, AL., Kalhorn, T.F., et al. (2003) "Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation", Blood, 101, 2043–2048.
   Google Scholar
• Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Samuel, S., Kapelushnik, J., et al. (1996) "Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleulcin-2 to treat leukemia relapse after allogeneic bone marrow transplantation", Blood, 87, 2195–2204.
   PubMed Web of Science ®Google Scholar